



Press Release 18th of August 2011

BioGaia signs exclusive agreement with Fleet Laboratories in U.S.

BioGaia has signed an agreement with Fleet Laboratories for the exclusive rights to sell BioGaia's Probiotic tablets with strawberry flavour in the U.S. and its territories (excluding Puerto Rico). Launch is planned to first quarter 2012.

Fleet will offer the probiotic tablets under its Pedia-Lax brand. Like BioGaia's other digestive health probiotic products, the tablets contain *L. reuteri* Protectis, a probiotic strain patented by BioGaia and one that has been involved in numerous clinical studies on digestive and immune health. BioGaia already works with C.B. Fleet's subsidiary Casen Fleet in Spain and Portugal, where several of its probiotic dietary supplements are selling well.

BioGaia's products are available in pharmacies in about 60 countries worldwide. In the U.S., in addition to the new deal with Fleet Laboratories, the BioGaia brand line of products is distributed by Everidis Health Sciences and includes BioGaia ProTectis Drops (for infants), BioGaia Probiotic Straws and BioGaia Chewable Tablets (in the original lemon flavour).

– We are very pleased that the agreement with Fleet Laboratories will provide an opportunity to broaden BioGaia's reach in the U.S., an important region with strong growth potential, says Peter Rothschild, President of BioGaia.

About Fleet Laboratories

Founded in 1960 and headquartered in Lynchburg, VA. Fleet Laboratories is a privately held manufacturer and marketer of products related to personal care and health care. Formerly doing business under the name C.B. Fleet and well-known for its line of laxative drug products, the company also markets a diverse range of cosmetic and pharmaceutical products in 100 countries around the world.

For additional information please contact:

Peter Rothschild, President, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2011-08-17 BioGaia AB Interim report 1 January – 30 June 2011

2011-08-04 BioGaia signs agreement with Moroccan pharmaceutical company Galenica SA for Morocco

2011-05-11 Annual General Meeting of BioGaia

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 18 August 2011, 3:00 pm CET.

***BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm.
www.biogaia.com***